Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 8/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 5/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | HTR1F | P30939 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL27730424 | 0.98 | TAAR1 (0.48) | TAAR1HTR2AMYCSLC6A2HMGB1 | |
| SCHEMBL1806284 | 0.89 | MYC (0.40) | TAAR1MYCHTR6TTRCYP1A2 | |
| SCHEMBL4202392 | 0.87 | MYC (0.47) | MYCTTRCYP1A2 | |
| SCHEMBL30446463 | 0.87 | MYC (0.47) | MYCTTRCYP1A2 | |
| SCHEMBL1806872 | 0.87 | MAOA (0.42) | TAAR1MYCTTRHRH1CYP1A2 | |
| SCHEMBL8954151 | 0.87 | MYC (0.39) | TAAR1MYCHTR6TTRCYP1A2 | |
| SCHEMBL28841517 | 0.87 | MYC (0.39) | TAAR1MYCHTR6TTRCYP1A2 | |
| SCHEMBL6295462 | 0.85 | CYP3A4 (0.43) | TAAR1MYCTTRHRH1CYP1A2 | |
| SCHEMBL16713743 | 0.85 | CYP3A4 (0.43) | TAAR1MYCTTRHRH1CYP1A2 | |
| SCHEMBL15578539 | 0.85 | CYP3A4 (0.43) | TAAR1MYCTTRHRH1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4001313-A | MANUFACTURE OF AROMATIC AMINO COMPOUNDS | OSAKA CITY (JA) | 1977-01-04 | — | — | US | claimed |
| EP-1773916-B1 | PROCESS FOR PREPARATION OF FUNCTIONALIZED POLYIMIDES | SABIC INNOVATIVE PLASTICS IP (NL) | 2014-02-12 | — | — | EP | disclosed |
| EP-2418256-B1 | Acid dyes | CLARIANT FINANCE BV LTD (VG) | 2013-03-27 | — | — | EP | disclosed |
| US-8404036-B2 | Water-soluble near-infrared absorbing coloring matters and aqueous inks containing same | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2013-03-26 | — | — | US | disclosed |
| EP-2418256-A1 | Acid dyes | Clariant International Ltd. (CH) | 2012-02-15 | — | — | EP | disclosed |
| US-8034787-B2 | Enzyme-cleavable prodrug compounds | MEDAREX, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20110123784-A1 | WATER-SOLUBLE NEAR-INFRARED ABSORBING COLORING MATTERS AND AQUEOUS INKS CONTAINING SAME | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2011-05-26 | — | — | US | disclosed |
| EP-2261253-A2 | Antibodies directed to Clostridium difficile | NEUTEC PHARMA PLC (GB) | 2010-12-15 | — | — | EP | disclosed |
| US-7816317-B2 | Tripeptide prodrug compounds | MEDAREX, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| EP-1613655-B1 | CLOSTRIDIUM DIFFICILE FOCUSSED ANTIBODIES | NEUTEC PHARMA PLC (GB) | 2010-08-11 | — | — | EP | disclosed |
| EP-1294405-A2 | PRODRUG COMPOUNDS CLEAVABLE BY THIMET OLIGOPEPTIDASE | CORIXA CORPORATION (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20020142955-A1 | Enzyme-cleavable prodrug compounds | E. R. SQUIBB & SONS, L.L.C. | 2002-10-03 | — | — | US | disclosed |
| WO-2002076939-A2 | CYSTEINE PROTEASE INHIBITORS | EXEGENICS INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| WO-2002000263-A2 | TRIPEPTIDE PRODRUG COMPOUNDS | MEDAREX, INC. (US) | 2002-01-03 | — | — | WO | disclosed |
| WO-2001095945-A2 | PRODRUG COMPOUNDS CLEAVABLE BY THIMET OLIGOPEPTIDASE | MEDAREX, INC. (US) | 2001-12-20 | — | — | WO | disclosed |
| EP-1144011-A2 | PRODRUG COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | Coulter Pharmaceutical, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000033888-A9 | PRODRUG COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | COULTER PHARM INC (US) | 2001-05-10 | — | — | WO | disclosed |
| WO-2000033888-A2 | PRODRUG COMPOUNDS AND PROCESS FOR PREPARATION THEREOF | COULTER PHARMACEUTICAL, INC. (US) | 2000-06-15 | — | — | WO | disclosed |
| US-5817877-A | Metal-catalyzed amination of organic sulfonates to organic amines | YALE UNIVERSITY (US) | 1998-10-06 | — | — | US | disclosed |
| US-4001313-A | MANUFACTURE OF AROMATIC AMINO COMPOUNDS | OSAKA CITY (JA) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110123784-A1 | WATER-SOLUBLE NEAR-INFRARED ABSORBING COLORING MATTERS AND AQUEOUS INKS CONTAINING SAME | IK, RB1, COL1A1 | TAAR1 1933/4885HTR2A 3632/4885MYC 3750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.